Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B

Hepatitis B, Chronic Clinical Trial

Official title:

A Single Arm, Multicenter, Open-label, 52-week, the Omnibus Extension Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B and Are HBV DNA PCR Negative at the End of Year 4 Treatment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00646503
• Other study ID #: CLDT600ACN04
• Status: Completed
• Phase: Phase 4
• First received: March 26, 2008
• Last updated: June 21, 2017
• Start date: March 2008
• Est. completion date: September 2009

Study information

• Verified date: June 2017
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will explore efficacy and safety of Telbivudine in the fifth year of treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: September 2009
• Est. primary completion date: September 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria

• Patient completed Omnibus study and will be available to immediately rollover into this study without discontinuation of study drug.

• Patient was not discontinued from the previous Omnibus study.

• Male or female, adult patients with CHB (HBeAg positive or HBeAg negative).

• Patient is willing and able to provide written informed consent to participate in the study.

• HBV DNA PCR undetectable in recent 12 months.

Exclusion criteria

• Pregnant or breastfeeding, or has plan of pregnant during study period.

• Patient is co-infected with hepatitis C virus (HCV), hepatitis D virus (HDV), r HIV at screening visit.

• Patient needs any anti-HBV treatment combination (add-on therapy) or switch to other anti HBV treatment from Telbivudine at investigator's discretion.

• Patient has any laboratory value abnormality that physicians think he/she may not be suitable to continue the Telbivudine treatment.

• Patient has any clinically significant concurrent severe or unstable disease conditions that physicians think he/she may have any additional risk or not be suitable to participate the study.

• Patient has evidence of renal insufficiency defined as patient requiring dialysis or having an estimated creatinine clearance below 50mL/min, as estimated by the cockcroft-Gault formula.

• Patient is currently abusing alcohol or illicit drugs.

• Patient is enrolled or plans to enroll in another clinical trial of an investigational agent while participating in this study.

• All other treatments for hepatitis B, including commercially available treatments indicated for conditions other than chronic hepatitis B that are being investigated to treat or may have activity against HBV (e.g., ribavirin, famciclovir, ganciclovir, etc.)

• Prolonged use of systemic acyclovir or famciclovir defined as episodic treatment with these agents for periods exceeding 10 days every 3 months, or chronic suppressive therapy.

• Systemic immunomodulators of any type.

• Systemic corticosteroids ( topical and inhaled corticosteroids are permitted).

• Herbal medications known to cause hepatotoxicity (e.g., St. John's Wart, Kava, Jin Bu Huan, Yuzhitang, germander, chaparral, shark cartilage, mistletoe, slim 10, Lipokinetix, etc.).

• Patient has any of the following laboratory values:

• Hemoglobin < 9 g/dL for menor <8 g/dL for women.

• Total WBC <1,500/mm3

• Absolute neutrophil count (ANC)<1,000/mm3

• Platelet count <30,000/mm3

• Serum albumin <2.5g/dL

• Total bilirubin =4×ULN

• Serum creatinine >1.5×ULN

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis B, Chronic
• Hepatitis, Chronic

Intervention

Drug:
• Telbivudine
600 mg/day, oral telbivudine for 52 weeks

Locations

Country	Name	City	State
China	Novartis Investigative Site	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Novartis

Country where clinical trial is conducted

China, 

References & Publications (1)

Hou JL, Xu D, Shi G, Wan M, Goodman Z, Tan D, Xie Q, Chen C, Wei L, Niu J, Wang Q, Ren H, Wang Y, Jia J, Bao W, Dong Y, Trylesinski A, Naoumov NV. Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Ch — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients experiencing serious adverse events (for all SAEs, and SAEs attributed to study drug). Proportion of patients experiencing adverse events, coded by body system ( all AEs, and AEs attributed to study drug).		At Baseline, Week 24 and Week 52
Secondary	For HBeAg-positive patients, Maintained Virologic Response, here defined as HBeAg loss and serum HBV DNA PCR negative (COBAS Amplicor PCR < 300 copies/ml) during the whole study period.		At Baseline, Week 24 and Week 52

External Links

•   Results for CLDT600ACN04 from the Novartis Clinical Trials website